PMID- 26436071
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20151005
LR  - 20200930
IS  - 2251-9572 (Print)
IS  - 2251-9580 (Electronic)
IS  - 2251-9572 (Linking)
VI  - 4
IP  - 3
DP  - 2015 Aug
TI  - Lower Doses of Bosentan in Combination With Sildenafil Might be Beneficial in 
      Pulmonary Arterial Hypertension.
PG  - e26487
LID - 10.5812/cardiovascmed.26487v2 [doi]
LID - e26487
AB  - BACKGROUND: Endothelin-receptor-antagonist, bosentan, has been found to improve 
      the functional capacity and cardiopulmonary hemodynamics in Pulmonary Arterial 
      Hypertension (PAH). Clinical trials have shown the preferable dosage of 125 mg, 
      twice daily, regarding both efficacy and safety. OBJECTIVES: The purpose of this 
      study was to investigate the effects of lower doses of bosentan (62.5 mg, twice 
      daily) in combination with sildenafil on exercise capacity and clinical events, 
      in 41 patients with idiopathic pulmonary hypertension or chronic thromboembolic 
      pulmonary hypertension (CTEPH). PATIENTS AND METHODS: We assigned 41 patients 
      with PAH (non-reactive idiopathic or non-operable chronic thromboembolic) to 
      receive 62.5 mg of bosentan twice daily as combination therapy and evaluated the 
      New York heart association (NYHA) functional class, 6-minutes-walk-distance 
      (6MWD), time to clinical worsening, echocardiographic indexes and clinical 
      events, for an average of 18.5 +/- 9.5 months. RESULTS: No adverse drug reaction 
      was observed during the follow-up. Clinical worsening occurred in six (14%) 
      patients, at least one year after treatment, two of the cases failed to respond 
      to 125 mg, twice daily and died. Eight (19%) remained in FC I_II, but didn't 
      reach the goal of 380 meters for 6MWD. All other patients reached the treatment 
      goals according to the latest European society of cardiology (ESC) guidelines. 
      CONCLUSIONS: We observed acceptable results regarding both efficacy and safety 
      with 62.5 mg of bosentan, twice daily in this group of patients. Further clinical 
      trials investigating PAH with lower dosages of bosentan may be warranted.
FAU - Amin, Ahmad
AU  - Amin A
AD  - Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, IR Iran.
FAU - Mohamadifar, Arezoo
AU  - Mohamadifar A
AD  - Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, IR Iran.
FAU - Taghavi, Sepideh
AU  - Taghavi S
AD  - Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, IR Iran.
FAU - Naderi, Nasim
AU  - Naderi N
AD  - Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, IR Iran.
FAU - Sadeghi, Hosnolah
AU  - Sadeghi H
AD  - Rajaie Cardiovascular, Medical and Research Center, Iran University of Medical 
      Sciences, Tehran, IR Iran.
LA  - eng
PT  - Journal Article
DEP - 20150801
PL  - India
TA  - Res Cardiovasc Med
JT  - Research in cardiovascular medicine
JID - 101608315
PMC - PMC4588707
OTO - NOTNLM
OT  - Bosentan
OT  - Chronic Thromboembolic Pulmonary Hypertension
OT  - Endothelin Receptor Antagonist
OT  - Pulmonary Hypertension
EDAT- 2015/10/06 06:00
MHDA- 2015/10/06 06:01
PMCR- 2015/08/01
CRDT- 2015/10/06 06:00
PHST- 2014/12/29 00:00 [received]
PHST- 2015/04/16 00:00 [revised]
PHST- 2015/04/25 00:00 [accepted]
PHST- 2015/10/06 06:00 [entrez]
PHST- 2015/10/06 06:00 [pubmed]
PHST- 2015/10/06 06:01 [medline]
PHST- 2015/08/01 00:00 [pmc-release]
AID - 10.5812/cardiovascmed.26487v2 [doi]
PST - epublish
SO  - Res Cardiovasc Med. 2015 Aug 1;4(3):e26487. doi: 10.5812/cardiovascmed.26487v2. 
      eCollection 2015 Aug.